The Middle East and Asia Pacific cell and gene therapy market comprises therapies that use genetically modified cells or genes to treat diseases such as cancer, cystic fibrosis, heart disease and neurological disorders. Cell therapy involves the use of stem cells, while gene therapy involves inserting a functional gene into a cell to compensate for a mutated gene that causes disease. These innovative therapies are showing promise in treating previously untreatable conditions by addressing the underlying cause of disease rather than just alleviating symptoms.
The Global Middle East and Asia Pacific cell and gene therapy market is estimated to be valued at US$ 4147.82 Th in 2024 and is expected to exhibit a CAGR of 7.5% over the forecast period 2024 to 2030.
Key players operating in the Middle East and Asia Pacific cell and gene therapy market are BASF SE, Croda Health Care, JRS Pharma, Lipoid GmbH, Azelis, U.K. Vet Chem, Gattefoss, Synergy API, Anzchem, Vantage. These players are focusing on new product launches, collaborations and geographic expansion to strengthen their market position. For instance, in 2022 BASF SE launched a new lipid excipient product line called Vivag® lipids to support cell and gene therapy developers.
There is high potential for cell and gene therapies in disease areas with high unmet needs such as cancer, cardiovascular disorders and neurological conditions. According to WHO, cancer burden is expected to grow by 70% over the next 20 years in Asia Pacific creating substantial market opportunities. In addition, rising healthcare expenditure, advanced healthcare infrastructure and investment in R&D by pharmaceutical companies are supporting the development of novel cell and gene therapies in the region.
Many biopharmaceutical players are investing in research facilities, manufacturing plants and collaborations in key Asian markets like China, India, Japan, South Korea and Australia to cater to the region's large patient population. For example, bluebird bio partnered with Chiesi Farmaceutici to commercialize its approved gene therapies Zynteglo and Skysona in Europe and other international markets including Asia Pacific. Such global expansion strategies by industry players are expected to propel cell and gene therapy market growth in the Middle East and Asia Pacific region.
Market drivers and restrain
One of the major market driver is the rising prevalence of chronic diseases like cancer, neurodegenerative disorders and cardiovascular diseases. According to WHO, non-communicable diseases accounted for almost 7 out of every 10 deaths in Asia. Cell and gene therapies offer promising alternatives for treating such chronic conditions and drive their higher adoption.
However, high costs associated with cell and gene therapy manufacturing and clinical trials pose a major challenge. Significant capital investment is required to set up commercial scale manufacturing facilities for advanced therapy products. The average cost of developing a new therapeutic is estimated to be over US$ 1 billion including opportunity costs. Such high development costs are passed on to patients making the treatments unaffordable for many. This acts as a key restraint for the Middle East and Asia Pacific cell and gene therapy market.
The Global Middle East And Asia Pacific Cell And Gene Therapy Market Size can be segmented based on therapy, application, vehicle type, and end user. The cell therapy segment dominates the market as it holds a larger market share and is witnessing higher adoption rates compared to gene therapy. Within cell therapy, the allogeneic therapies sub-segment holds the largest market share due to lower costs involved compared to autologous or personalized therapies. The oncology application segment holds the largest share of the cell and gene therapy market due to a high disease prevalence and rising demand for advanced treatment options. Viral vectors are widely used as vehicles for cell and gene therapies due to their high transduction efficiency and ability to deliver therapeutic genes. Hospitals and clinics form the major end users for cell and gene therapies in the region.
On the basis of region, Asia Pacific holds the largest share of the Middle East and Asia Pacific Cell and Gene Therapy Market and is expected to witness the highest growth during the forecast period. This is due to growing incidences of cancer and other target diseases, rising healthcare expenditure, increasing adoption of advanced therapeutics, and supportive regulatory environment provided by countries. China, Japan, and India dominate the regional market due to their large population base and significant unmet medical needs. However, countries in the Middle East such as Saudi Arabia and United Arab Emirates are also emerging as high potential markets attributable to their universal healthcare systems and investments in the commercialization of advanced treatment technologies.
Explore more information on this topic, Please visit-